Nutrients and cancer treatment

International Journal of Integrative Medicine

Volumn 1, Issue 1, 1999, Pages 22-28

  Simone, Charles B ^a   Simone, Nicole L ^b   Simone II, Charles B ^b  

^a Simone Protective Cancer Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343108896     PISSN: 15226255     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Clemens MR, Muller-Ladner CI, Gey KF: Vitamins during high dose chemo- and radiotherapy. Z Ernahrungswiss 31(2):110-120, 1992.
2. Clemens MR: Vitamins and therapy of malignancies. Ther Umsch 51(7): 483-488, 1994.
3. Faber M, Coudray C, Hida H, Mousseau M, Favier A: Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin: a preliminary study. Biol Trace Elem Res 47(1-3):117-123, 1995.
4. Henquin N, Havivi E, Reshef A, Barak F, Horn Y: Nutritional monitoring and counselling for cancer patients during chemotherapy. Oncology 46(3):173-177, 1989.
5. Doroshow JH, Locker GY, Ifrim I, Myers CE: Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 68:1053-1064, 1981.
6. Dorr RT: Cytoprotective agents for anthracyclines. Seminars Oncol 23:23-34, 1996.
7. Yoda Y, Nakazawa M, Abe T, Kawakami Z: Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. Cancer Res 46:2561-2566, 1986.
8. Speyer J, Green MD, Kramer E, Rey M, Sanger J, et al: Protective effect of ICRF-187 against doxorubicin-induced cardiac toxicity in women with breast cancer. NEJM 319:745-752, 1988.
9. Speyer J, Green MD, Zeleniuh-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992.
10. Carlson R: Reducing the cardiotoxicity of the anthracyclines. Oncology 6(6):95-108, 1992.
11. Ripoll EAP, Rama BN, Webber MM: Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. J Urol 136(2):529-531, 1986.
12. Pieters R, Huismans DR, Loonen AH, Hahlen K, Veerman AJ: Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients. Jap J Cancer Res 82(9):1051-1055, 1991.
13. Van Vleet JF, Greenwood L, Ferands VJ, Rebar AH: Effect of selenium and vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vit Res 39:997-1010, 1980.
14. Fujita K, Shinpo K, Sato T, Niime H, Shamoto M, et al: Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res 42:309-316, 1982.
15. Sonnevald P: Effect of alpha-tocopherol on cardiotoxicity of adriamycin in the rat. Cancer Treatment Rep 62:961-962, 1976.
16. VanVleet JF, Greenwood L, Ferands VJ, Rebar AH: Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vit Res 39:997-1010, 1978.
17. Myers CE, McGuire WP, Young R: Adriamycin amelioration of toxicity by alpha-tocopherol. Cancer Treatment Rep 60:961-962, 1976.
18. Myers CE, McQuire WP, Liss PH, Ifrim I: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167, 1977.
19. Mills EE: Retinoids and cancer. Soc R Radiotherap and Congress, May 13, 1982.
20. Okunieff P: Interactions between ascorbic acid and the radiation of bone marrow, skin, and tumor. Am J Clin Nutr 54:1281-1283S, 1991.
21. Meadows G, Pierson HF, Abdallah RM: Ascorbate in the treatment of experimental transplanted melanoma. Am J Clin Nutr 54:1284S-1291S, 1991.
22. Taper HS, Roberfroid M, Bonte J, et al: Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer 40:575-579, 1987.
23. Crary EJ, McCarty MF: Potential clinical applications for high-dose nutritional antioxidants. Medical Hypothesis 13(1):77-98, 1984.
24. Seifter E, Rettura A, Padawar J, et al: Vitamin A and beta-carotene as adjunctive therapy to tumor excision, radiation therapy and chemotherapy. In: Vitamins, Nutrition and Cancer, pp. 1-19. Prasad KN (ed). Karger: Basel, 1984.
25. Trizna Z, Shantz SP, Lee JJ, Spitz MR, Goepfert H, et al: In vitro protective effect of chemoprotective agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral lymphocytes of head and neck cancer patients. Cancer Detect Prev 17:575-583, 1993.
26. Srinivasan V, Jacobs AL, Simpson SA, Weiss JF: Radioprotection by vitamin E effect on hepatic enzymes, delayed type hypersensitivity and post-irradiation survival in mice. In: Modulations and Mediations of Cancer Cells by Vitamins, pp. 119-131. Meyskens FL Jr, Prasad KN (eds). Karger: Basel, 1983.
27. Malick MA, Roy RM, Sternberg J: Effect of vitamin E on post irradiation death in mice. Experientia 34:1216-1217, 1978.
28. Londer HM, Myers CE: Radioprotective effects of vitamin E. Am J Clin Nutr 31:705a, 1978.
29. Shen RN, Mendecki J, Friedenthal E, Botstein C, et al: Antitumour activity of radiation and vitamin A used in combination on Lewis lung carcinoma, p. 145. Thirty-first annual meeting of the Radiation Research Society, San Antonio, Feb. 27, 1983.
30. Seifter E, Rettura A, Padawar J, et al: C3HBA tumor therapy with radiation, beta-carotene and vitamin A. A two year follow-up. Fed Proc 42:768, 1983.
31. Carini R, Poli G, Dianzani MU, Maddix SP, Slater TF, Cheeseman KH: Comparative evaluation of the amount of the antioxidant activity of alpha-tocopherol, alpha-tocopherol polythylene glycol 1000 succinate and alpha tocopherol succinate in isolated hepatocytes and liver microsomal suspensions. Biochem Pharmacol 39:1597, 1990.
32. Prasad KN, Rama BN: Modification of the effect of pharmacological agents, ionizing radiation and hyperthermia on tumor cells by vitamin E. In: Vitamin, Nutrition and Cancer, p. 76. Prasad KN (ed). Karger: Basel, 1984.
33. Kim JH, He SQ, Dragovic J, et al: Use of vitamins as adjunct to conventional cancer therapy. In: Nutrients in Cancer Prevention and Treatment, pp. 363-372. Prasad KN, Santamaria L, Williams RM (eds). New Jersey: Humana Press, 1995.
34. Wood LA: Possible prevention of adriamycin-induced alopecia by tocopherol. NEJM 312(16):1060, 1985.
35. Komiyama S, Kudoh S, Yanagita T, Kuwano M: Synergistic combination of 5FU, vitamin A, and cobalt-60 radiation for head and neck tumors: antitumor combination therapy with vitamin A. Auris, Nasus, Larynx 12(S2):S239-S243, 1995.
36. Israel L, Hajji O, Grefft-Alami A, Desmoulins D, et al: Vitamin A augmentation of the effects of chemotherapy in metastatic breast cancers after menopause: randomized trial in 100 patients. Annnles De Medecine Interne 136(7):551-554, 1985.
37. Nagoumey, et al: Menadiol with chemotherapies: feasibility for resistance modification. Proc Ann Meet Am Soc Clin Oncol 6:A132, 1987.
38. Ladner HL, et al: In: Vitamins and Cancer, p. 429. Meyskens FL (ed). Clifton: Humana Press, 1986.
39. Sakamoto A, et al: In: Medulation and Mediation of Cancer by Vitamins, p. 330. Karger: Basel, 1983.
40. Smyth J, et al: Glutathione may prevent cisplatin toxicity, raise response rates in ovarian cancer. Oncology News 4(1):1-4, 1995.
41. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996.
42. Schein P: Results of chemotherapy and radiation therapy protection trials with WR-2721. Cancer Investigation 10(1):24-26, 1992.
43. Schuchter LM, Luginbuhl WE, Meropol NJ: The current status of toxicity protectants in cancer therapy. Semin Oncol 19:742-745, 1992.
44. Coleman N, Bump E, Kramer R: Chemical modifiers of cancer treatment. J Clin Oncol 6:709-733, 1988.
45. Yuhas JM, Spellman JM, Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3:211-216, 1980.
46. Kligerman M, Glover D, Turrisi A, Simone CB, et al: Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 10:1773-1776, 1984.
47. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide- and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996.
48. Dousay L, Mu C, Giarratana MC, et al: Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood. 88:2849-2855, 1995.
49. Schiller JH, Storer B, Berlin J, et al: Amifostine, cisplatin and vinblastine in metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 14:1913-1921, 1996.
50. Santamaria, Benazzo, et al: First clinical case-report (1980-88) of cancer chemoprevention with beta-carotene plus canthaxanthin supplemented to patients after radical treatment. In: Nutrition, Growth and Cancer. Tryfiates GP, Prasad KN (eds). New York: Alan R. Liss, 1988.
51. Jaakkola K, Lahteenmaki P, Laaksa J, Harju E, et al: Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small cell lung cancer: Anticancer Res 12(3):599-606, 1992.
52. Henriksson, Rogo KO, Grankvist K: Interaction between cytostatics and nutrients. Med Oncol Tumor Pharmacother 8(2):79-86, 1991.
53. Leeb BF: Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheum 13:459-463, 1995.
54. Simone CB, Simone NL, Simone CB II: Folic acid does not interfere with methotrexate. The Lancet 350:1556, 1997.
55. Simone CB, Simone NL, Simone CB II: Lifestyle modification in oncology care. Prasad KN (ed). In: Cancer and Nutrition. Amsterdam: IOS Press, 1998.
56. Simone CB: Use of therapeutic levels of nutrients to augment oncology care. In: Adjuvant Nutrition in Cancer Treatment, p. 72. Quillin P, Williams M (eds): Tulsa: Academic Press 1992.
57. Simone CB: Cancer and Nutrition: A Ten Point Plan to Decrease Your Risk of Getting Cancer. New York: McGraw-Hill, 1981; revised, Garden City Park: Avery Publishing Group, 1992.
58. Hoffer A, Pauling L: Hardin Jones biostatistical analysis of mortality data for cohorts of cancer patients with a large surviving fraction surviving at the termination of the study using vitamin C and other nutrients. J Orthomolecular Medicine 5(3):143, 1990.
59. Goodman MT, Kolonel LN, Wilkens LR, Yoshizawa CN, LeMarchand L, Hankin JH: Dietary factors in lung cancer prognosis. European J Cancer 28(2-3):495-501, 1992.
60. Foster HD: Lifestyle influences on spontaneous cancer regression. Intl J Biosocial Research 10(1):17-20, 1988.
61. Carter JP: Macrobiotic diet and cancer survival. J Am College Nutr 12(3):209-215, 1993.
62. Sakamoto G, Hartmann WH, et al. In: Modulation and Mediation of Cancer by Vitamins, p. 330. Karger: Basel, 1983.
63. Lamm DL: Megadose vitamins in bladder cancer: a double blind clinical trial. J Urol 151:21-26, 1994.
64. Wynder E, Kajitani T, Kuno J, Lucas J, Palo A, Farrow J: A comparison of survival rates between American and Japanese patients with breast cancer. Surg Gyn Obstet 196-200, August 1963.
65. Donegan WL, Hartz AJ, Rimm AA: The association of body weight with recurrent cancer of the breast. Cancer 41:1590-1594, 1978.
66. Sohrabi A, Sandoz J, Spratt JS, Polk HC: Recurrence of breast cancer: Obesity, tumor size, and axil-lary lymph node metastases. JAMA 244:261-265, 1980.
67. Boyd NF, Campbell JE, Germanson T, Thomson DB, Sutherland DJ, Meakin JW: Body weight and prognosis in breast cancer. JNCI 67: 785-789, 1981.
68. Tartter PI, Papatestas AE, Ioannovich J, Mulvihill MN, Lesnick G, Aifees AH: Cholesterol and obesity as prognostic factors in breast cancer. Cancer 47:2222-2227, 1981.
69. Chen J, et al: Antioxidant status and cancer mortality in China. Int J Epidemiol 21(4):625-635, 1992.
70. Li JY, et al: Nutrition intervention trials in Linxian, China: multiple vitamin and mineral supplementation, cancer incidence and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85:1492-1498, 1993.